Clarifications for Primary and Secondary Outcomes and Analyses
- PMID: 37707831
- PMCID: PMC10502690
- DOI: 10.1001/jamaophthalmol.2023.4206
Clarifications for Primary and Secondary Outcomes and Analyses
Erratum for
-
Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial.JAMA Ophthalmol. 2023 Oct 1;141(10):990-999. doi: 10.1001/jamaophthalmol.2023.2097. JAMA Ophthalmol. 2023. PMID: 37261839 Free PMC article.
References
-
- Zadnik K, Schulman E, Flitcroft I, et al. ; CHAMP Trial Group Investigators . Efficacy and safety of 0.01% and 0.02% atropine for the treatment of pediatric myopia progression over 3 years: a randomized clinical trial. JAMA Ophthalmol. Published online June 1, 2023. doi:10.1001/jamaophthalmol.2023.2097 - DOI - PMC - PubMed
